lenvatinib + sintilimab

Lenvatinib + sintilimab is a combination therapy consisting of two agents: lenvatinib, an oral small molecule multikinase inhibitor, and sintilimab, a monoclonal antibody targeting the programmed cell death protein 1 (PD-1). Lenvatinib inhibits multiple receptor tyrosine kinases involved in tumor angiogenesis and proliferation, including vascular endothelial growth factor receptors (VEGFR1–3), fibroblast growth factor receptors (FGFR1–4), platelet-derived growth factor receptor alpha (PDGFRα), RET, and KIT. Sintilimab blocks PD-1 on T cells to enhance antitumor immune responses by preventing its interaction with PD-L1/PD-L2. The combination leverages both antiangiogenic effects and immune checkpoint inhibition for synergistic antitumor activity. This regimen has been investigated primarily in advanced hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (iCCA) as second-line or conversion therapy after chemotherapy failure or for patients unsuitable for surgery[1][2][10].

Brand names

Lenvima (for lenvatinib)Tyvyt (for sintilimab)

Other names

lenvatinib plus sintilimabsintilimab plus lenvatinib